Call for help to killer cells improves cancer rejection

(Press-News.org) Sometimes it takes a long time to solve a puzzle: In 1893, German surgeon G. Reinbach discovered that tumor tissue is often infiltrated by special cells of the immune system called eosinophils. Ever since then, scientists have been trying to figure out if and how these cells, which are part of the innate immune system, are involved in cancer rejection. "There are many studies that link the presence of eosinophils in a tumor with an improved prognosis of the disease. However, even 120 years after Reinbach's discovery, it still remained elusive whether or not eosinophils actively play a role in fighting the tumor," says Prof. Günter Hämmerling from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). Immunologist Hämmerling hypothesized that tumor eosinophils might act as mediators that call for help to other immune cells, thus initiating an immune defense against the tumor. Most prior studies had not taken into account the involvement of other components of the immune system. Dr. Rafael Carretero from Hämmerling's department has now been able to confirm this hypothesis. Carretero discovered that eosinophils release special agents that attract the immune system's "professional killers" into cancer tissue. These immune cells, called CD8+ T cells, then go ahead and attack the tumor. Mice whose eosinophils had been incapacitated using antibodies exhibited poor defense mechanisms against tumors and soon succumbed to the disease. In these animals, strikingly low quantities of CD8+ T cells infiltrated the tumor. Carretero also showed that the agents released by the eosinophils are, in fact, responsible for attracting the T cells. To prove this, he used antibodies to catch these attractants. Under these circumstances, hardly any T cells invaded the tumor. Nor was it possible to attract T cells into the tumor when the researchers transplanted non-activated eosinophils, which do not produce attractants, into the mice. An important approach in advanced cancer medicine is to treat cancer using a patient's immune cells after first arming the cells against the tumor in culture. However, these therapies often fail because insufficient numbers of T cells reach the tumor. Carretero and his colleagues therefore investigated whether the outcomes of these immunotherapies might be improved by adding eosinophils. While transplantation of T cells alone had only little impact on tumor size in cancerous mice, the researchers achieved substantial regression of the cancer by transplanting both T cells and activated eosinophils. Mice that had received this combination survived significantly longer than animals in the control group that had received only T cells. In subsequent experiments, the investigators showed that eosinophils alone - in the absence of T cells - fail to improve cancer rejection. Apart from their call for help to killer cells, eosinophils had another impact on the immediate environment of a tumor. They normalized blood vessels in the tumor, thus additionally contributing to tumor rejection. "We have solved a 100-year-old puzzle here and we have shown that eosinophils initiate cancer rejection by sending out a molecular call for help," says Hämmerling, the study head. He adds: "This knowledge will enable us to significantly enhance cellular immunotherapies by guiding more T cells into a tumor." His team is currently studying cases in which cancer patients have been treated by immunotherapy. The researchers want to find out if and how higher levels of eosinophils correlate with better treatment outcomes.

INFORMATION:

Rafael Carretero, Ibrahim M Sektioglu, Natalio Garbi, Oscar C Salgado, Philipp Beckhove & Günter J Hämmerling: Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells. Nature Immunology 2015, DOI:10.1038/ni.3159

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.